145 related articles for article (PubMed ID: 34987881)
1. Predictive Modeling for Clinical Features Associated With Neurofibromatosis Type 1.
Morris SM; Gupta A; Kim S; Foraker RE; Gutmann DH; Payne PRO
Neurol Clin Pract; 2021 Dec; 11(6):497-505. PubMed ID: 34987881
[TBL] [Abstract][Full Text] [Related]
2. Optic Pathway Glioma in Children with Neurofibromatosis Type 1: A Multidisciplinary Entity, Posing Dilemmas in Diagnosis and Management Multidisciplinary Management of Optic Pathway Glioma in Children with Neurofibromatosis Type 1.
Lohkamp LN; Parkin P; Puran A; Bartels UK; Bouffet E; Tabori U; Rutka JT
Front Surg; 2022; 9():886697. PubMed ID: 35592129
[TBL] [Abstract][Full Text] [Related]
3. Does attention-deficit-hyperactivity disorder exacerbate executive dysfunction in children with neurofibromatosis type 1?
Payne JM; Arnold SS; Pride NA; North KN
Dev Med Child Neurol; 2012 Oct; 54(10):898-904. PubMed ID: 22845611
[TBL] [Abstract][Full Text] [Related]
4. Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center study.
Henning AM; Handrup MM; Kjeldsen SM; Larsen DA; Ejerskov C
Orphanet J Rare Dis; 2021 Nov; 16(1):489. PubMed ID: 34809690
[TBL] [Abstract][Full Text] [Related]
5. Identification of Mutation Regions on
Xu M; Xiong H; Han Y; Li C; Mai S; Huang Z; Ai X; Guo Z; Zeng F; Guo Q
Front Genet; 2018; 9():270. PubMed ID: 30087692
[TBL] [Abstract][Full Text] [Related]
6. Autism and attention-deficit/hyperactivity disorders and symptoms in children with neurofibromatosis type 1.
Morotti H; Mastel S; Keller K; Barnard RA; Hall T; O'Roak BJ; Fombonne E
Dev Med Child Neurol; 2021 Feb; 63(2):226-232. PubMed ID: 32406525
[TBL] [Abstract][Full Text] [Related]
7. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort.
Falzon K; Drimtzias E; Picton S; Simmons I
Br J Ophthalmol; 2018 Oct; 102(10):1367-1371. PubMed ID: 29343527
[TBL] [Abstract][Full Text] [Related]
8. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
9. Clustering of mutations in the 5' tertile of the NF1 gene in Slovakia patients with optic pathway glioma.
Bolcekova A; Nemethova M; Zatkova A; Hlinkova K; Pozgayova S; Hlavata A; Kadasi L; Durovcikova D; Gerinec A; Husakova K; Pavlovicova Z; Holobrada M; Kovacs L; Ilencikova D
Neoplasma; 2013; 60(6):655-65. PubMed ID: 23906300
[TBL] [Abstract][Full Text] [Related]
10. Attention Deficit Hyperactivity Disorder in Neurofibromatosis Type 1: Evaluation with a Continuous Performance Test.
Cohen R; Halevy A; Aharon S; Shuper A
J Clin Neurol; 2018 Apr; 14(2):153-157. PubMed ID: 29629523
[TBL] [Abstract][Full Text] [Related]
11. NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat.
Azizi AA; Walker DA; Liu JF; Sehested A; Jaspan T; Pemp B; Simmons I; Ferner R; Grill J; Hargrave D; Driever PH; Evans DG; Opocher E;
Neuro Oncol; 2021 Jan; 23(1):100-111. PubMed ID: 32628746
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic factors of neurofibromatosis type 1-associated optic pathway gliomas in children].
Florent C; Beylerian M; Mairot K; Dambricourt L; André N; David T; Girard N; Audic F; Denis D
J Fr Ophtalmol; 2022 Feb; 45(2):173-184. PubMed ID: 34972579
[TBL] [Abstract][Full Text] [Related]
13. Feedback-Based Learning of Timing in Attention-Deficit/Hyperactivity Disorder and Neurofibromatosis Type 1.
Prochnow A; Bluschke A; Novotna B; von der Hagen M; Beste C
J Int Neuropsychol Soc; 2022 Jan; 28(1):12-21. PubMed ID: 33573707
[TBL] [Abstract][Full Text] [Related]
14. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
15. Treatment of ADHD in neurofibromatosis type 1.
Mautner VF; Kluwe L; Thakker SD; Leark RA
Dev Med Child Neurol; 2002 Mar; 44(3):164-70. PubMed ID: 12005317
[TBL] [Abstract][Full Text] [Related]
16. Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.
Brown JA; Emnett RJ; White CR; Yuede CM; Conyers SB; O'Malley KL; Wozniak DF; Gutmann DH
Hum Mol Genet; 2010 Nov; 19(22):4515-28. PubMed ID: 20826448
[TBL] [Abstract][Full Text] [Related]
17. Quantitative MRI demonstrates abnormalities of the third ventricle subventricular zone in neurofibromatosis type-1 and sporadic paediatric optic pathway glioma.
Boonzaier NR; Hales PW; D'Arco F; Walters BC; Kaur R; Mankad K; Cooper J; Liasis A; Smith V; O'Hare P; Hargrave D; Clark CA
Neuroimage Clin; 2020; 28():102447. PubMed ID: 33038669
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment Endocrine Disorders Due to Optic Pathway Gliomas in Pediatric Neurofibromatosis Type 1: Multicenter Study.
Santoro C; Perrotta S; Picariello S; Scilipoti M; Cirillo M; Quaglietta L; Cinalli G; Cioffi D; Di Iorgi N; Maghnie M; Gallizia A; Parpagnoli M; Messa F; De Sanctis L; Vannelli S; Marzuillo P; Miraglia Del Giudice E; Grandone A
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32294191
[TBL] [Abstract][Full Text] [Related]
19. Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas.
Johnson KJ; Fisher MJ; Listernick RL; North KN; Schorry EK; Viskochil D; Weinstein M; Rubin JB; Gutmann DH
Fam Cancer; 2012 Dec; 11(4):653-6. PubMed ID: 22829012
[TBL] [Abstract][Full Text] [Related]
20. Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome.
King A; Listernick R; Charrow J; Piersall L; Gutmann DH
Am J Med Genet A; 2003 Oct; 122A(2):95-9. PubMed ID: 12955759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
